Phase 3 trial of leniolisib in activated PI3Kδ syndrome, dabrafenib plus trametinib in relapsed/refractory hairy cell leukemia, and TγδLGL leukemia as a more symptomatic subset of leukemia
Blood Podcast
00:00
PI3K Delta Signaling in APDS
Laniolicib is an orally bioavailable small molecule inhibitor engineered to selectively target PI3K delta signaling. In a recent dose-finding study conducted in six patients with APDS, the authors reported that Laniolicib was well tolerated and effective at reducing PI3KDelta pathway hyperactivity. Most available therapies do not target hyperactive PI3K Delta signaling.
Transcript
Play full episode
